InterSystems, a global leader in healthcare information systems and technology solutions, has signed an agreement with Pure Health, the largest laboratory operator in the Gulf countries, to deploy InterSystems’ TrakCare Lab Enterprise (TCLE) system, the first and only laboratory business management solution, to support the UAE’s testing initiatives for SARS-CoV-2.
InterSystems is a creative data technology provider dedicated to helping customers solve the most critical scalability, interoperability and speed problems in their business operations. Pure Health is a pioneering healthcare solutions provider and the largest laboratory network in the entire Gulf region with 115 laboratories and employing a total of 750 healthcare professionals across the nation.
Under this initiative, InterSystems’ web-based TCLE system will enable Pure Health to streamline testing workflows and make data easily accessible from all parties, thereby accelerating testing for SARS-CoV-2 in the UAE.
Pure Health has two dedicated SARS-CoV-2 testing laboratories in the emirates of Abu Dhabi and Sharjah, in addition to opening one more laboratory in Dubai in the coming week. With this, the organisation will have the largest SARS-CoV-2 testing capability in the Middle East with the capacity to perform 25,000 tests daily.
TrakCare Lab Enterprise is an automated platform that reads and collects patient data, resulting in minimal manual input and accelerating the screening process. It is designed to help laboratories transform from a reactive testing and results service – typically supported by a traditional data and analytical management solution – to a data-driven organisation capable of meeting the increased expectations for modern pathology services.
The capability of conducting high volumes of SARS-CoV-2 polymerase chain reaction (PCR) tests daily is instrumental in combating the current pandemic, and TCLE can manage tens of thousands of PCR tests daily. This high-throughput processing capability helps accelerate the diagnosis and identification of suspected cases, the release of recovered patients and the screening of close contacts and high-risk groups.
